DISPOSITION OF CEFTAZIDIME IN FEBRILE GRANULOCYTOPENIC CANCER PATIENT

头孢他啶在发热性粒细胞减少性癌症患者中的处置

• 批准号: 4691975
• 负责人: P K NARANG
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/4691975
• 关键词: antibacterial agents; cephalosporins; dosage; drug adverse effect; drug metabolism; granulocytopenia; human subject; human therapy evaluation; myelogenous leukemia; neoplasm /cancer chemotherapy; pharmacokinetics

Pharmacokinetic parameters and interpatient variability is assessed in 80 febrile granulocytopenic cancer patients being treated with a third generation cephalosporin-ceftazidime. Disposition in this population appears to be significantly different than that observed in normal volunteers. Elimination half-life is prolonged by almost 50-60% in these patients. Overall treatment success in the study, with ceftazidime alone was 80% and exceeded 90% on the addition of an antigungal agent. Significant variability (60-85%) in drug disposition was observed in these patients due to an underlying disease. Although the hybrid elimination rate appears to be normally distributed, both total systemic clearance and distribution volumes reveal skewed distributions. Statistical analysis suggests that distribution of these parameters in this population may be log-normal and hence may necessitate drug monitoring to optimize drug dosage in an attempt to minimize both the toxicity and patient cost.

在80例患者中评估药代动力学参数和患者间变异性 发热性粒细胞减少性癌症患者正在接受第三种治疗 一代头孢菌素-头孢他啶。 该人群的分布 似乎与正常人中观察到的显著不同， 志愿者 这些药物的消除半衰期延长了近50-60%， 患者 研究中头孢他啶单药治疗的总体成功率 在添加抗菌剂的情况下，其抑菌率为80%和90%以上。 在这些研究中观察到药物分布的显著变异性（60-85%）， 患者由于基础疾病。 虽然混血儿的淘汰 总的全身清除率和 分布量显示出偏态分布。 统计分析 表明这些参数在该人群中的分布可能是 对数正态，因此可能需要药物监测以优化药物 剂量，以尽量减少毒性和患者成本。